

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/385695388>

Role of Heme Oxygenase-1 in Sickle Cell Anemia-Related Oxidative Stress: A Narrative Review

Article in General medicine and Clinical Practice · September 2024

DOI: 10.31579/2639-4162/222

CITATIONS

0

READS

8

1 author:



[Emmanuel Ifeanyi Obeagu](#)

Africa University

2,100 PUBLICATIONS 36,090 CITATIONS

SEE PROFILE

Role of Heme Oxygenase-1 in Sickle Cell Anemia-Related Oxidative Stress: A Narrative Review

Emmanuel Ifeanyi Obeagu

Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science.

*Corresponding Author: Adrian Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science.

Received date: September 02, 2024; Accepted date: September 18, 2024; Published date: September 27, 2024

Citation: Emmanuel I. Obeagu, (2024), Role of Heme Oxygenase-1 in Sickle Cell Anemia-Related Oxidative Stress: A Narrative Review, *J. General Medicine and Clinical Practice*, 7(16); DOI:10.31579/2639-4162/222

Copyright: © 2024, Emmanuel Ifeanyi Obeagu. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Sickle Cell Anemia (SCA) is a genetic disorder characterized by the production of hemoglobin S, leading to chronic hemolysis, vaso-occlusive crises, and elevated oxidative stress. Heme oxygenase-1 (HO-1), an enzyme responsible for the breakdown of heme, plays a critical role in mitigating oxidative stress by converting heme into biliverdin, iron, and carbon monoxide (CO). This narrative review explores the role of HO-1 in the context of SCA-related oxidative stress, focusing on its mechanisms of action, interactions with oxidative stress pathways, and potential therapeutic implications. HO-1's ability to reduce oxidative damage and inflammation highlights its significance as a therapeutic target for managing the oxidative burden in SCA. In SCA, the breakdown of sickled red blood cells (RBCs) releases free heme, which contributes to oxidative stress and inflammation. HO-1 helps counteract these effects by catalyzing the degradation of heme and producing antioxidant by-products such as bilirubin. Bilirubin and CO exhibit protective properties, including ROS scavenging and anti-inflammatory effects, which are crucial for managing oxidative stress and maintaining vascular health. Additionally, HO-1's role in regulating iron availability and modulating inflammatory pathways further underscores its protective functions in SCA.

Kew Words: sickle cell anemia; heme oxygenase-1; oxidative stress; antioxidant defense; therapeutic strategies

Introduction

Sickle Cell Anemia (SCA) is a severe, inherited blood disorder characterized by the presence of hemoglobin S (HbS), which causes red blood cells (RBCs) to adopt a rigid, sickle-shaped form under low oxygen conditions. This morphological change leads to chronic hemolysis, vaso-occlusive crises, and widespread inflammation. One of the key pathological features of SCA is oxidative stress, which arises from the breakdown of sickled RBCs and the subsequent release of free hemoglobin and heme into the bloodstream. This review focuses on heme oxygenase-1 (HO-1), an enzyme that plays a critical role in managing oxidative stress by degrading heme into non-toxic by-products. [1-5] Heme oxygenase-1 (HO-1) is an inducible enzyme responsible for the catabolism of heme, a pro-oxidant molecule, into biliverdin, free iron, and carbon monoxide (CO). The process of heme degradation is crucial in reducing oxidative stress, as it removes heme from the circulation, thus preventing its contribution to oxidative damage. Biliverdin, which is subsequently converted to bilirubin, exhibits strong antioxidant properties and helps protect cells from oxidative injury. CO, a by-product of HO-1 activity, has been shown to have anti-inflammatory effects and can modulate vascular tone. These actions collectively contribute to reducing oxidative stress and inflammation, which are prevalent in SCA. [6-10] In the context of SCA, elevated oxidative stress has several detrimental effects on cellular function and overall health. The sickling of RBCs leads to the release of free heme, which exacerbates oxidative damage and contributes to inflammation. The excessive generation of reactive oxygen species (ROS) results in cellular damage, reduced nitric oxide

availability, and endothelial dysfunction. This environment promotes the progression of vaso-occlusive crises and further complicates the management of the disease. HO-1 helps mitigate these effects by breaking down free heme and thereby reducing oxidative stress. [11-15]

HO-1 is regulated by various signaling pathways that respond to oxidative stress. The expression of HO-1 is typically upregulated in response to high levels of ROS, acting as a cellular defense mechanism. The enzyme's induction is mediated through transcription factors such as nuclear factor erythroid 2-related factor 2 (Nrf2), which regulates the expression of several antioxidant and cytoprotective genes. Understanding these regulatory mechanisms is essential for developing therapeutic strategies aimed at enhancing HO-1 activity to manage oxidative stress in SCA. [16-20] The protective effects of HO-1 extend beyond its antioxidant activity. The enzyme's role in iron metabolism is significant, as it sequesters free iron released during heme degradation, preventing it from catalyzing further oxidative reactions. Additionally, HO-1-derived CO has been shown to have anti-inflammatory effects, which are beneficial in reducing the chronic inflammation characteristic of SCA. By modulating these pathways, HO-1 contributes to the overall reduction in disease severity and improvement in patient outcomes. [21-25] Given the critical role of HO-1 in managing oxidative stress and inflammation, it presents a promising target for therapeutic interventions in SCA. Pharmacological agents that induce HO-1 expression or mimic its effects could potentially provide relief from the

oxidative burden and inflammation associated with the disease. Similarly, gene therapy approaches aimed at enhancing HO-1 activity may offer novel treatment options for patients with SCA. [26-30]

Role of Heme Oxygenase-1 in Oxidative Stress

Heme oxygenase-1 (HO-1) plays a critical role in managing oxidative stress through its ability to degrade heme, a potent pro-oxidant. The primary function of HO-1 is to catalyze the breakdown of heme into biliverdin, free iron, and carbon monoxide (CO). This process not only reduces the availability of free heme—thereby mitigating its pro-oxidant effects—but also generates by-products that exert antioxidant and anti-inflammatory properties. [31-33] The breakdown of heme by HO-1 results in the production of biliverdin, which is subsequently converted to bilirubin. Both biliverdin and bilirubin have well-documented antioxidant properties. Bilirubin, in particular, is a potent scavenger of reactive oxygen species (ROS) and has been shown to protect cells from oxidative damage. By converting heme into these less harmful products, HO-1 effectively reduces the oxidative load on cells, protecting them from damage associated with excessive ROS. [34-38] Free heme breakdown also releases free iron into the circulation. However, the excess iron can catalyze further oxidative reactions through the Fenton reaction, exacerbating oxidative stress. HO-1 mitigates this risk by sequestering the released iron in a form that is less available for oxidative reactions. This regulation of iron homeostasis helps to prevent iron-induced oxidative damage and maintains cellular integrity. [39-42] Carbon monoxide (CO), another by-product of heme degradation by HO-1, has several beneficial effects related to oxidative stress. CO acts as a signaling molecule with anti-inflammatory properties and can modulate vascular tone. It has been shown to reduce the production of pro-inflammatory cytokines and prevent the activation of inflammatory pathways. By modulating these processes, CO contributes to the reduction of oxidative stress and inflammation. [43-46] HO-1 induction is part of a broader cellular response to oxidative stress. The enzyme's expression is regulated by transcription factors such as nuclear factor erythroid 2-related factor 2 (Nrf2), which also upregulates other antioxidant and cytoprotective genes. This coordinated response enhances the cell's overall ability to manage oxidative stress and reduce damage caused by ROS.⁴⁷ In various disease contexts, including Sickle Cell Anemia (SCA), the role of HO-1 becomes particularly significant. In SCA, the breakdown of sickled red blood cells releases large amounts of heme, contributing to oxidative stress and inflammation. HO-1's ability to degrade heme and produce antioxidant by-products is crucial in mitigating these effects and protecting against the complications associated with SCA, such as vaso-occlusive crises and tissue damage.⁴⁸

Mechanisms of HO-1 Action in Sickle Cell Anemia

Heme oxygenase-1 (HO-1) is a key enzyme in the body's response to oxidative stress, and its role is particularly significant in Sickle Cell Anemia (SCA), where it helps modulate the adverse effects of oxidative damage. The mechanisms through which HO-1 exerts its protective effects in SCA are multifaceted, involving the degradation of heme, modulation of oxidative stress, regulation of inflammation, and interaction with iron metabolism.⁴⁹ HO-1 catalyzes the degradation of heme, a process that transforms heme into biliverdin, free iron, and carbon monoxide (CO). This reaction is crucial for managing oxidative stress in SCA because free heme, released from lysed sickled red blood cells (RBCs), can contribute to the production of reactive oxygen species (ROS) through Fenton reactions. By converting heme into biliverdin and subsequently into bilirubin, HO-1 helps neutralize excess ROS. Bilirubin, a potent antioxidant, scavenges ROS and reduces oxidative damage to cells and tissues. This antioxidant activity is essential in counteracting the oxidative stress resulting from chronic hemolysis and vaso-occlusive events in SCA.^[50] Another significant mechanism of HO-1 action in SCA is its role in regulating iron homeostasis. The degradation of heme by HO-1 releases free iron, which can catalyze the formation of ROS through Fenton chemistry if not properly sequestered. HO-1 mitigates this risk by promoting the sequestration of free iron in ferritin or binding it to transferrin, thus preventing the excess iron from contributing to further

oxidative stress. By controlling iron levels and reducing the potential for iron-induced oxidative damage, HO-1 helps protect cells from the detrimental effects of oxidative stress and inflammation. [51] HO-1 also influences inflammation through its by-products. Carbon monoxide (CO), produced during heme degradation, has been shown to have anti-inflammatory effects. CO can modulate the activity of inflammatory cells and reduce the expression of pro-inflammatory cytokines. In SCA, chronic inflammation is a significant issue, exacerbating the disease's symptoms and complications. By reducing the production of inflammatory cytokines and mitigating inflammatory responses, HO-1 helps alleviate the inflammatory component of SCA and contributes to overall disease management.^[52]

HO-1's ability to influence the cellular redox state is another critical aspect of its function. The enzyme's activity helps to maintain a balance between oxidative and reductive processes within cells. By reducing the levels of pro-oxidant heme and enhancing the production of antioxidant by-products, HO-1 stabilizes the cellular redox environment. This stabilization is particularly important in SCA, where the chronic oxidative stress from sickled RBCs and hemolysis can overwhelm cellular defenses. HO-1's modulation of the redox state contributes to the protection of cellular components from oxidative damage and supports cellular resilience.^[53] HO-1 expression is regulated by several cellular stress responses, including those mediated by the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway. In SCA, oxidative stress and inflammatory signals can induce HO-1 expression as part of the cellular defense mechanism. The activation of Nrf2 leads to the transcription of HO-1 and other antioxidant genes, which collectively enhance the cell's ability to cope with oxidative damage. This induction of HO-1 is a key adaptive response that helps mitigate the harmful effects of elevated oxidative stress and inflammation in SCA.⁵⁴ HO-1's effects on vascular health are also relevant to SCA management. The enzyme's by-products, particularly CO, have vasodilatory properties that can improve blood flow and reduce the frequency of vaso-occlusive crises. By enhancing endothelial function and modulating vascular tone, HO-1 helps prevent or alleviate the blockages in blood vessels that are characteristic of SCA. This vascular protection contributes to reducing the severity of complications associated with the disease. [55]

HO-1 and the Regulation of Inflammatory Pathways

Heme oxygenase-1 (HO-1) plays a pivotal role in the regulation of inflammatory pathways, which is crucial for managing diseases characterized by chronic inflammation, such as Sickle Cell Anemia (SCA). This enzyme, through its by-products and interactions with various cellular pathways, modulates inflammatory responses and helps mitigate the adverse effects of inflammation.^[56] One of the primary by-products of HO-1 activity is carbon monoxide (CO), which has well-documented anti-inflammatory properties. CO influences inflammation by interacting with various cellular signaling pathways. It can inhibit the expression of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF- α) and interleukin-1 beta (IL-1 β) by blocking the activation of nuclear factor kappa B (NF- κ B), a key transcription factor involved in inflammation. CO also reduces the production of reactive oxygen species (ROS) and limits oxidative stress, further contributing to its anti-inflammatory effects. In SCA, where chronic inflammation exacerbates disease symptoms, CO's ability to modulate these inflammatory pathways is particularly beneficial. [57] Another by-product of HO-1 activity, bilirubin, is known for its strong antioxidant properties. Bilirubin scavenges ROS and prevents oxidative damage, thereby reducing inflammation. Elevated bilirubin levels, resulting from increased HO-1 activity, are associated with reduced levels of inflammatory markers and improved clinical outcomes in conditions with high oxidative stress. In SCA, where oxidative stress and inflammation are closely linked, the antioxidant and anti-inflammatory properties of bilirubin help alleviate some of the inflammatory damage and protect against vascular complications.^[55]

HO-1 also influences immune cell function, which is critical in controlling inflammation. The enzyme affects the activity of various immune cells, including macrophages, neutrophils, and lymphocytes. HO-1 can alter macrophage polarization, promoting an anti-inflammatory M2 phenotype

over the pro-inflammatory M1 phenotype. This shift helps reduce tissue damage and inflammatory responses. Additionally, HO-1 affects neutrophil activation and migration, further modulating the inflammatory process. By influencing these immune cells, HO-1 contributes to the regulation of inflammation and helps manage inflammatory conditions associated with SCA.[56] HO-1 impacts the production of cytokines, which are central to the inflammatory process. By modulating the NF- κ B signaling pathway, HO-1 reduces the expression of pro-inflammatory cytokines and enhances the production of anti-inflammatory cytokines. This regulation helps balance the inflammatory response and prevent excessive inflammation, which can contribute to tissue damage and disease progression in SCA. The ability of HO-1 to modulate cytokine levels is a key aspect of its role in managing inflammation. HO-1 interacts with various immune signaling pathways to regulate inflammation. For example, the enzyme influences the activation of the Nrf2 pathway, which controls the expression of antioxidant and anti-inflammatory genes. By activating Nrf2, HO-1 promotes the transcription of genes that counteract oxidative stress and inflammation. Additionally, HO-1 affects the mitogen-activated protein kinase (MAPK) pathways, which are involved in cellular responses to stress and inflammation. These interactions highlight the enzyme's role in integrating multiple signaling pathways to modulate inflammatory responses.[57] HO-1 also plays a role in maintaining endothelial function, which is crucial for vascular health and inflammation. The enzyme's by-products, particularly CO, can improve endothelial cell function by reducing oxidative stress and inflammation. This protection helps prevent endothelial dysfunction, which is a key factor in the pathogenesis of vaso-occlusive crises in SCA. By supporting endothelial health, HO-1 contributes to the overall regulation of inflammation and vascular integrity.[57]

Conclusion

Heme oxygenase-1 (HO-1) plays a pivotal role in modulating inflammatory responses in Sickle Cell Anemia (SCA) through its diverse mechanisms of action. By degrading heme into biliverdin, carbon monoxide (CO), and free iron, HO-1 helps to counteract oxidative stress and inflammation, which are central to the pathophysiology of SCA. Biliverdin and its derivative bilirubin serve as potent antioxidants, reducing oxidative damage and inflammation, while CO exerts anti-inflammatory effects by interacting with key signaling pathways and reducing the production of pro-inflammatory cytokines. The enzyme's impact extends to the regulation of immune cell function and cytokine production. HO-1 influences macrophage polarization, promoting an anti-inflammatory M2 phenotype over the pro-inflammatory M1 phenotype. It also modulates the activity of other immune cells, such as neutrophils and lymphocytes, contributing to the overall balance of the inflammatory response. By affecting these cellular processes, HO-1 helps mitigate the chronic inflammation and tissue damage characteristic of SCA.

References

1. Alenzi FQ, AlShaya DS. (2019). Biochemical and molecular analysis of the beta-globin gene on Saudi sickle cell anemia. *Saudi Journal of Biological Sciences*;26(7):1377-1384.
2. Obeagu EI, Ochei KC, Nwachukwu BN, Nchuma BO. (2015). Sickle cell anaemia: a review. *Scholars Journal of Applied Medical Sciences*;3(6B):224422-224452.
3. Obeagu EI. (2020). Erythropoietin in Sickle Cell Anaemia: A Review. *International Journal of Research Studies in Medical and Health Sciences*;5(2):22-28.
4. Obeagu EI. Sickle Cell Anaemia: Haemolysis and Anemia. *Int. J. Curr. Res. Chem. Pharm. Sci.* 2018;5(10):20-21.
5. Obeagu EI, Muhimbura E, Kagenderezo BP, Uwakwe OS, Nakweyune S, Obeagu GU. (2022). An Update on Interferon Gamma and C Reactive Proteins in Sickle Cell Anaemia Crisis. *J Biomed Sci*;11(10):84.
6. Sbodio JI, Snyder SH, Paul BD. (2019). Redox mechanisms in neurodegeneration: from disease outcomes to therapeutic

- opportunities. *Antioxidants & Redox Signaling.* ;30(11):1450-1499.
7. Kovacic P, Somanathan R. (2012). Redox processes in neurodegenerative disease involving reactive oxygen species. *Current neuropharmacology*;10(4):289-302.
8. La Rosa P, Petrillo S, Bertini ES, Piemonte F. (2020). Oxidative stress in DNA repeat expansion disorders: a focus on NRF2 signaling involvement. *Biomolecules*;10(5):702.
9. Obeagu EI, Bunu UO, Obeagu GU, Habimana JB. (2023). Antioxidants in the management of sickle cell anaemia: an area to be exploited for the wellbeing of the patients. *International Research in Medical and Health Sciences*;6(4):12-17.
10. Obeagu EI, Ogunnaya FU, Obeagu GU, Ndidi AC. (2023). Sickle cell anaemia: a gestational enigma. *European Journal of Biomedical and Pharmaceutical Sciences*;10(9): 72-75
11. Obeagu EI. (2018). An update on micro-RNA in sickle cell disease. *Int J Adv Res Biol Sci*; 5:157-158.
12. Obeagu EI, Babar Q. (2021). Covid-19 and Sickle Cell Anemia: Susceptibility and Severity. *J. Clinical and Laboratory Research*;3(5):2768-2487.
13. Obeagu EI. (2023). Depression in Sickle Cell Anemia: An Overlooked Battle. *Int. J. Curr. Res. Chem. Pharm. Sci*;10(10):41-42.
14. Renoux C, Joly P, Faes C, Mury P, Eglenen B, et al., (2018). Association between oxidative stress, genetic factors, and clinical severity in children with sickle cell anemia. *The Journal of pediatrics*; 195:228-235.
15. Gueye Tall F, Martin C, Ndour EH, Faes C, Deme Ly I, et al., (2020). Influence of oxidative stress biomarkers and genetic polymorphisms on the clinical severity of hydroxyurea-free senegalese children with sickle cell anemia. *Antioxidants*;9(9):863.
16. Juan CA, Pérez de la Lastra JM, Plou FJ, Pérez-Lebeña E. (2021). The chemistry of reactive oxygen species (ROS) revisited: outlining their role in biological macromolecules (DNA, lipids and proteins) and induced pathologies. *International journal of molecular sciences*;22(9):4642.
17. Obeagu EI, Obeagu GU. (2023). Evaluation of Hematological Parameters of Sickle Cell Anemia Patients with Osteomyelitis in A Tertiary Hospital in Enugu, Nigeria. *Journal of Clinical and Laboratory Research*;6(1):2768-0487.
18. Obeagu EI, Dahir FS, Francisca U, Vandu C, Obeagu GU. (2023). Hyperthyroidism in sickle cell anaemia. *Int. J. Adv. Res. Biol. Sci*;10(3):81-89.
19. Swem CA, Ukaejiofo EO, Obeagu EI, Eluke B. (2018). Expression of micro-RNA 144 in sickle cell disease. *Int. J. Curr. Res. Med. Sci*;4(3):26-32.
20. Obeagu EI. (2018). Sickle cell anaemia: Historical perspective, Pathophysiology and Clinical manifestations. *Int. J. Curr. Res. Chem. Pharm. Sci*;5(11):13-15.
21. Obeagu EI, Obeagu GU. (2023). Sickle Cell Anaemia in Pregnancy: A Review. *International Research in Medical and Health Sciences.* Jun 10;6(2):10-13.
22. Silva M, Faustino P. (2023). From stress to sick (le) and back again—oxidative/antioxidant mechanisms, genetic modulation, and cerebrovascular disease in children with sickle cell anemia. *Antioxidants*;12(11):1977.
23. Deng M, Sun J, Peng L, Huang Y, Jiang W, et al., (2022). Scutellarin acts on the AR-NOX axis to remediate oxidative stress injury in a mouse model of cerebral ischemia/reperfusion injury. *Phytomedicine*; 103:154214.
24. Obeagu EI, Mohamod AH. (2023). An update on Iron deficiency anaemia among children with congenital heart disease. *Int. J. Curr. Res. Chem. Pharm. Sci*;10(4):45-48.
25. Edward U, Osuorji VC, Nnodim J, Obeagu EI. (2022). Evaluation of Trace Elements in Sickle Cell Anaemia Patients

- Attending Imo State Specialist Hospital, Owerri. *Madonna University journal of Medicine and Health Sciences* ISSN: 2814-3035. Mar 4;2(1):218-234.
26. Umar MI, Aliyu F, Abdullahi MI, Aliyu MN, Isyaku I, Aisha BB, Sadiq RU, Shariff MI, Obeagu EI. Assessment Of Factors Precipitating Sick Cell Crises Among Under 5-Years Children Attending Sick Cell Clinic of Murtala Muhammad Specialist Hospital, Kano. *blood*;11:16.
 27. Obeagu EI. (2018). Vaso-occlusion and adhesion molecules in sickle cells disease. *Int J Curr Res Med Sci*;4(11):33-35.
 28. Liu Z, Zhou T, Ziegler AC, Dimitrion P, Zuo L. (2017). Oxidative stress in neurodegenerative diseases: from molecular mechanisms to clinical applications. *Oxidative medicine and cellular longevity*;1(1):2525967.
 29. Ifeanyi OE, Stella EI, Favour AA. (2018). Antioxidants In the Management of Sick Cell Anaemia. *Int J Hematol Blood Disord (Internet)* (cited 2021 Mar 4); 3.
 30. Buhari HA, Ahmad AS, Obeagu EI. (2023). Current Advances in the Diagnosis and Treatment of Sick Cell Anaemia. *APPLIED SCIENCES (NIJBAS)*. 4(1).
 31. Nnodim J, Uche U, Ifeoma U, Chidozie N, Ifeanyi O, ET ALL., (2015). Hepcidin and erythropoietin level in sickle cell disease. *British Journal of Medicine and Medical Research*;8(3):261-265.
 32. Obeagu EI. (2023). BURDEN OF CHRONIC OSTEOMYELITIS: REVIEW OF ASSOCIATED FACTORS. *Madonna University journal of Medicine and Health Sciences*;3(1):1-6.
 33. Obeagu EI, Obeagu GU. (2024). Oxidative Damage and Vascular Complications in Sick Cell Anemia: A Review. *Elite Journal of Haematology*;2(3):58-66.
 34. Gueye Tall F, Martin C, Ndour EH, Faes C, Deme Ly I, ET ALL., (2020). Influence of oxidative stress biomarkers and genetic polymorphisms on the clinical severity of hydroxyurea-free senegalese children with sickle cell anemia. *Antioxidants*;9(9):863.
 35. Silva DG, Junior EB, de Souza Torres L, Júnior OR, et al., (2011). Bonini-Domingos CR, De Almeida EA. Relationship between oxidative stress, glutathione S-transferase polymorphisms and hydroxyurea treatment in sickle cell anemia. *Blood Cells, Molecules, and Diseases*;47(1):23-28.
 36. Consoli V, Sorrenti V, Grosso S, Vanello L. (2021). Heme oxygenase-1 signaling and redox homeostasis in physiopathological conditions. *Biomolecules*;11(4):589.
 37. Aloh GS, Obeagu EI, Okoroiwu IL, Odo CE, Chibunna OM, et al., (2015). Antioxidant-Mediated Heinz Bodies Levels of Sick Erythrocytes under Drug-Induced Oxidative Stress. *European Journal of Biomedical and Pharmaceutical sciences*;2(1):502-507.
 38. Obeagu EI, Obeagu GU. (2023). Sick Cell Anaemia in Pregnancy: A Review. *International Research in Medical and Health Sciences*; 6 (2): 10-13.
 39. Obeagu EI, Ogbuabor BN, Ikechukwu OA, Chude CN. (2014). Haematological parameters among sickle cell anemia patients' state and haemoglobin genotype AA individuals at Michael Okpara University of Agriculture, Umudike, Abia State, Nigeria. *International Journal of Current Microbiology and Applied Sciences*;3(3):1000-1005.
 40. Ifeanyi OE, Nwakaego OB, Angela IO, Nwakaego CC. (2014). Haematological parameters among sickle cell anaemia... Emmanuel Ifeanyi, et al. pdf• Obeagu. *Int. J. Curr. Microbiol. App. Sci*;3(3):1000-1005.
 41. Obeagu EI, Opoku D, Obeagu GU. (2023). Burden of nutritional anaemia in Africa: A Review. *Int. J. Adv. Res. Biol. Sci*;10(2):160-163.
 42. Ifeanyi E. (2015). Erythropoietin (Epo) Level in Sick Cell Anaemia (HbSS) With Falciparum Malaria Infection in University Health Services, Michael Okpara University of Agriculture, Umudike, Abia State, Nigeria. *PARIPEX - INDIAN JOURNAL OF RESEARCH*; 4(6): 258-259
 43. Ifeanyi OE, Nwakaego OB, Angela IO, Nwakaego CC. (2014). Haematological parameters among sickle cell anaemia patients in steady state and haemoglobin genotype AA individuals at Michael Okpara, University of Agriculture, Umudike, Abia State, Nigeria. *Int. J. Curr. Microbiol. App. Sci*;3(3):1000-1005.
 44. Ifeanyi OE, Stanley MC, Nwakaego OB. (2014). Comparative analysis of some haematological parameters in sickle cell patients in steady and crisis state at Michael Okpara University of agriculture, Umudike, Abia state, Nigeria. *Int. J. Curr. Microbiol. App. Sci*;3(3):1046-1050.
 45. Ifeanyi EO, Uzoma GO. (2020). Malaria and The Sick Cell Trait: Conferring Selective Protective Advantage to Malaria. *J Clin Med Res*; 2:1-4.
 46. Obeagu EI, Obeagu GU. (2024). Oxidative Damage and Vascular Complications in Sick Cell Anemia: A Review. *Elite Journal of Haematology*; 2 (3):58-66.
 47. Obeagu EI, Obeagu GU. (2024). Addressing Myths and Stigmas: Breaking Barriers in Adolescent Sick Cell Disease Education. *Elite Journal of Health Science*;2(2):7-15.
 48. Obeagu EI, Obeagu GU. (2024). Implications of climatic change on sickle cell anemia: A review. *Medicine*. Feb 9;103(6): e37127.
 49. Singh P, O'Toole TE, Conklin DJ, Hill BG, Haberzettl P. (2021). Endothelial progenitor cells as critical mediators of environmental air pollution-induced cardiovascular toxicity. *American Journal of Physiology-Heart and Circulatory Physiology*;320(4):H1440-1455.
 50. Al-Naama LM, Hassan MA, Mehdi JK. (2015). Association of erythrocytes antioxidant enzymes and their cofactors with markers of oxidative stress in patients with sickle cell anemia. *Qatar medical journal*;2015(2):14.
 51. Obeagu EI. Chromium VI: (2024). A Silent Aggressor in Sick Cell Anemia Pathophysiology. *Elite Journal of Haematology*; 2 (3):81-95.
 52. Obeagu EI. (2024). Maximizing longevity: erythropoietin's impact on sickle cell anemia survival rates. *Annals of Medicine and Surgery*;10-97.
 53. Obeagu EI, Ubosi NI, Obeagu GU, Egba SI, Bluth MH. (2024). Understanding apoptosis in sickle cell anemia patients: Mechanisms and implications. *Medicine*;103(2): e36898.
 54. Obeagu EI, Ayogu EE, Anyanwu CN, Obeagu GU. (2024). Drug-Drug Interactions in the Management of Coexisting Sick Cell Anemia and Diabetes. *Elite Journal of Health Science*;2(2):1-9.
 55. Obeagu EI, Obeagu GU. (2024). Dual Management: Diabetes and Sick Cell Anemia in Patient Care. *Elite Journal of Medicine*;2(1):47-56.
 56. Wood KC, Hsu LL, Gladwin MT. (2008). Sick cell disease vasculopathy: a state of nitric oxide resistance. *Free radical biology and medicine*;44(8):1506-1528.
 57. Tewari S, Brousse V, Piel FB, Menzel S, Rees DC. (2015). Environmental determinants of severity in sickle cell disease. *Haematologica*;100(9):1108.



This work is licensed under Creative Commons Attribution 4.0 License

To Submit Your Article Click Here: **Submit Manuscript**

DOI:[10.31579/2639-4162/222](https://doi.org/10.31579/2639-4162/222)

Ready to submit your research? Choose Auctores and benefit from:

- fast, convenient online submission
- rigorous peer review by experienced research in your field
- rapid publication on acceptance
- authors retain copyrights
- unique DOI for all articles
- immediate, unrestricted online access

At Auctores, research is always in progress.

Learn more <https://www.auctoresonline.org/journals/general-medicine-and-clinical-practice>